The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Jyseleca tablet (Filgotinib Maleate) 100 milligram (mg) and 200 mg in this post marketing setting: (1) Serious adverse events and adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in precautions for use (3) Known adverse drug reactions (4) Non-serious adverse events and adverse drug reactions (5) Other safety and effectiveness related information will be evaluated in accordance with the permitted articles under the actual conditions of use in Korea.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants With Serious Adverse Events (SAEs)
Timeframe: From the date of enrollment up to 24 weeks
Number of Participants With Adverse Drug Reactions (ADRs)
Timeframe: From the date of enrollment up to 24 weeks
Number of Participants With Unexpected AEs
Timeframe: From the date of enrollment up to 24 weeks
Number of Participants With Unexpected ADRs
Timeframe: From the date of enrollment up to 24 weeks
Number of Participants With Known ADRs
Timeframe: From the date of enrollment up to 24 weeks
Number of Participants With Non-serious AEs
Timeframe: From the date of enrollment up to 24 weeks
Number of Participants With Non-serious ADRs
Timeframe: From the date of enrollment up to 24 weeks
Change From Baseline in Disease Activity Score 28 Based on C-Reactive Protein (DAS28-CRP) at Week 12 and Week 24
Timeframe: Baseline, Week 12 and Week 24
Change From Baseline in the Mayo Clinic Score (MCS) at Week 12 and Week 24
Timeframe: Baseline, Week 12 and Week 24